טוען...
Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer
BACKGROUND: Despite major advancements in immunotherapy among a number of solid tumors, response rates among ovarian cancer patients remain modest. Standard treatment for ovarian cancer is still surgery followed by taxane- and platinum-based chemotherapy. Thus, there is an urgent need to develop nov...
שמור ב:
| הוצא לאור ב: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6668091/ https://ncbi.nlm.nih.gov/pubmed/31362778 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0654-5 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|